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Lipoprotem phospholipid composition and LCAT activity in nephrotic
and analbuminemic rats. Albumin is an acceptor of lysophosphatidyl-
choline (LPC), product of the lecithin:cholesterol acyl transferase
(LCAT) reaction, and it has been suggested that low LCAT activity and
reduced cholesterol esterification rate in patients with the nephrotic
syndrome may be linked to depletion of albumin. Effects of low plasma
albumin levels on LCAT activity, cholesterol esterification rates and
LPC-binding were therefore studied in hyperlipidemic nephrotic (NS)
and analbuminemic (NAR) rats. LPC-binding was also measured in
normoalbuminemic rats with dietary hypercholesterolemia. Remark-
ably, LCAT activity, measured with excess exogenous substrate, was
not decreased but increased in both NAR and NS rats. Molar esterifi-
cation rates with endogenous substrate were increased in NAR but
normal in NS rats. In normoalbuminemic rats, with or without hyper-
cholesterolemia, LPC was primarily found in the lipoprotein-deficient
plasma and the HDL3 fraction. In NAR and NS rats LPC levels were
increased in lipoproteins (notably in LDL and HDL2), but, in marked
contrast to normoalbuminemic rats, decreased in lipoprotein-deficient
plasma. Phosphatidylcholine, quantitatively the major phospholipid,
was distributed proportionally over the lipoproteins in NS, NAR and
control rats. Therefore, in hypoalbuminemia and analbuminemia LPC is
mainly bound to lipoproteins, which is in contrast to the paucity of LPC
in these particles in normoalbuminemic rats. Cholesterol esterification
in nephrotic plasma is thus not impaired by lack of an acceptor for
LPC-binding. The absence of an increase in molar cholesterol esterifi-
cation in conjunction with increased LCAT activity points to a possible
defect of the substrate for this reaction in nephrotic plasma. Increased
LPC levels in LDL, a characteristic of oxidized LDL, may be a hitherto
unrecognized atherosclerotic risk factor in the nephrotic syndrome.
The cholesterylesters present in plasma are derived from two
sources. One part is synthesized by acyl CoA:cholesterol acyl-
transferase and secreted into blood from the intestine and liver in
nascent lipoproteins, while another part is synthesized in plasma
by lecithin:cholesterol acyltransferase (LCAT) [1, 21. The latter
enzyme transfers fatty acids from the 2-position of phosphatidyl-
choline (PC) to cholesterol, resulting in the formation of lysophos-
phatidyicholine (LPC) and cholesterol ester [1]. Cholesterol ester-
ffication in plasma contributes to the formation of larger HDL2
from small HDL3 particles [2]. The plasma cholesterol esterifica-
tion process is essential for maintaining the gradient of free
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cholesterol between cells and HDL, which is necessary for
reversed cholesterol transport: the flow of cholesterol from cells to
plasma [3, 4]. Thus, cholesterol esterification may play a key role
in the prevention of atherosclerosis [4].
A low HDL2 cholesterol level has been observed in the
nephrotic syndrome in humans [5, 6]. The reduction in HDL2
cholesterol has been attributed to a reduction in the cholesterol
esterification rate due to a reduction in LCAT activity [7, 81.
However, in one of these studies [7] LCAT activity, measured
with exogenous substrate appeared normal, whereas fractional
esterification of endogenous cholesterol was reduced. The latter
is merely due to the high level of free cholesterol in the total
lipoprotein mass in these hyperlipidemic patients, most of
which is not directly available as substrate for the LCAT
reaction. In a recent report LCAT activity, measured with
exogenous substrate, was even found to be increased in ne-
phrotic subjects [9]. In rats with hypoalbuminemia due to
experimentally-induced nephrosis LCAT activity is also in-
creased [10], and HDL cholesterylester levels are high [11, 12].
Thus, in the nephrotic syndrome LCAT activity measured with
exogenous substrate appears to be unchanged or increased
rather than decreased.
Albumin is an acceptor of lysophosphatidylcholine (LPC)
product of the LCAT reaction [13]. Thus, hypoalbuminemia
could theoretically disturb cholesterol esterification [7]. How-
ever, no information is available on the distribution of LPC
between albumin and other potential ligands of LPC in ne-
phrotic plasma. In plasma from non-proteinuric analbuminemic
rats we observed high HDL2 levels as well as an increased
cholesterol esterification rate [14]. Similarly, two patients with
hereditary analbuminemia also demonstrated high LCAT activ-
ity [15]. Thus, low albumin levels as such do not appear to be
linked to a defect in cholesterol esterification. If plasma choles-
terol esteriflcation is reduced in the nephrotic syndrome in the
presence of increased LCAT activity measured with excess
exogenous substrate [9], this must be due to a factor other than
hypoalbuminemia.
In the present study we document the concentration of the
phospholipids PC and LPC and their distribution in lipoproteins
and lipoprotein-deficient plasma, as well as LCAT activity and
cholesterol esterification rates in hypoalbuminemic plasma ob-
tained from rats with experimental nephrotic syndrome and
from analbuminemic rats. Comparing these two models enables
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separation of the effects of hypoalbuminemia per se from those
linked to other abnormalities in plasma that are the result of
proteinuria. In addition, to determine whether alterations in PC
or LPC distribution in lipoproteins are related to hypoalbumin-
emia or are simply the consequence of hyperlipidemia, we
measured phospholipid concentration and distribution in nor-
moalbuminemic rats with hypercholesterolemia induced by
dietary cholesterol supplementation.
Methods
Animals
Male Sprague-Dawley rats (N = 41) were purchased from
Harlan-Olac (GB). Twenty-four were fed a standard rat chow
containing 21.4% animal and vegetable protein (RMHBR,
Hope Farms, Woerden, The Netherlands), except where oth-
erwise specified. The remainder were fed a semisynthetic diet
containing 20% casein (Hope Farms) throughout the experi-
ment. All were allowed water ad libitum. The protocol was
approved by the Utrecht University Board for study in exper-
imental animals.
Nephrotic syndrome
Twelve six-week-old animals, weighing 175 to 200 g, were
injected with adriamycin (Adriblastina RTUR, Farmitalia Carlo
Erba S.A., Nivelles, Belgium) into a tail vein, six at a dose of
3 mg/kg, and six at a dose of 4 mg/kg to induce nephrotic
syndrome (NS). Eleven similarly aged animals were injected
with an equal volume of isotonic saline. The rats treated with
the low dose of adriamycin and six of the controls were fed the
standard rat chow, and were sacrificed after seven months, by
which time a profound proteinuria and hyperlipidemia had
developed [161. These rats were used for measuring plasma
LCAT activity as well as phospholipid composition. The rats
injected with the higher dose of adriamycin and the control rats
were fed the semisynthetic diet and sacrificed after seven
weeks. The latter group was only used for measuring plasma
phospholipid composition.
Analbuminemia
Male three-month-old pathogen-free Nagase analbuminemic
rats (N = 12) were derived from our own colony (which was
founded with animals generously donated by Dr. S. Nagase,
Tokyo, Japan). Six similarly aged Sprague-Dawley rats served
as controls for the analbuminemic rats (NAR). These animals
were fed the semisynthetic diet.
Dietary cholesterol
Twelve three-month-old Sprague-Dawley rats were fed either
the standard rat chow (N = 4), or the standard chow supple-
mented with 2% dietary cholesterol (N = 4), or the standard
chow supplemented with 2% dietary cholesterol and 0.5%
cholic acid (N = 4). The animals were sacrificed after being
exposed to these diets for 14 days.
Urine was collected in the NS rats and their controls. The
rats were placed in macrolon metabolism cages, and had free
access to food and water. One day was allowed for acclimati-
zation. Subsequently two consecutive 24-hour urine samples
were collected. All animals were exsanguinated in the fed state
by puncture of the abdominal aorta under fentanyl-fluanisone
(Hypnorm', Janssen, Beerse, Belgium; 0.5 mllkg i.p.)-diaze-
pam anesthesia. Blood was collected in chilled K-EDTA coated
tubes and immediately centrifuged at 4°C for 10 minutes at 1000
x g. Plasma for cholesterol esterification analyses was stored at
—80°C until analyzed. Lipoprotein phospholipid determination
was performed in fresh plasma. Urinary protein was determined
by the Bradford method. Plasma albumin was determined by
electrophoresis. Creatinine in plasma and urine was determined
colorimetrically.
Lecithin: cholesterol acyltransferase (LCAT) activity
measured with endogenous or excess
exogenous substrates
Plasma LCAT activity was determined by two different
procedures, one of which utilizes endogenous substrate and the
other excess exogenous substrate. The molar rate of cholesterol
esterification refers to the esterification rate of endogenous
unesterified cholesterol in plasma. For this assay undiluted
plasma was incubated for one hour at 37°C. The esterification
rate is constant during this period and is expressed as nmol
cholesterol esterified/ml plasma/hr [17].
The plasma level of active LCAT was determined using
excess exogenous substrate, containing [3H]cholesterol, as
described [18]. Incubations were for six hours at 37°C in a total
volume of 0.145 ml, using 0.01 to 0.02 ml of rat plasma. The
reaction was stopped by addition of 0.30 ml of methanol.
Subsequently the lipids were extracted twice with 0.4 ml
hexane. Unesterified and esterified cholesterol were separated
using disposable silica columns, and [3H] cholesterylesters
were eluted with 3.0 ml hexane:diethylether (6:1, vollvol) [19]
and counted in a liquid scintillation counter. The measured
activities are linear with the amount of rat plasma used and the
within-day coefficient of variation of the LCAT assay using
exogenous substrate is 4.5%. The assays were performed in
duplicate and the measured activities are related to the activi-
ties in a human reference plasma pool that was included in each
run. It should be noted that the measured LCAT activity using
exogenous substrate reflects the activity of the enzyme as such,
and is independent of the endogenous lipoproteins present in
the plasma sample.
Lipoprotein isolation by density-gradient ultracentrifugation
Plasma lipoproteins were separated by density-gradient ultra-
centrifugation into seven fractions (chylomicrons and VLDL,
d < 1.006 g/ml; intermediate density lipoprotein, IDL, d 1.006
to 1.019 g/ml; low density lipoprotein, LDL1, d 1.019 to 1.04
g/ml; LDL2, 1.04 to 1.063; high density lipoprotein, HDL2, d
1.063 to 1.125 g!ml; HDL3, d 1.125 to 1.21 gIml and lipoprotein-
deficient plasma (LDP) with a d > 1.21 g/ml) [14]. Three
experimental and three control samples were analyzed in each
run. Cholesterol and phospholipid concentrations were assayed
enzymatically using kits (respectively Boehringer GmbH,
Mannheim, Germany and bioMrieux, Marcy-l'Etoile, France).
Recovery of cholesterol and phospholipid after ultracentrifuga-
tion was 104.9 1.0 and 105.8 3.3%, respectively.
Phospholipid composition of lipoproteins and lipoprotein-
deficient plasma analyzed by thin-layer chromatography
Lipoproteins derived from plasma from two to three animals
in each group were pooled depending on the phospholipid
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concentration. Phospholipids were extracted in a stepwise
fashion. First with a mixture of methanol (2.53 x fraction
volume) and chloroform (1.27 x fraction volume), then with
chloroform and water (both 1.27 x fraction volume). The
chloroform fraction was then evaporated, and the residue
dissolved in 2 ml chloroform:methanol (2:1, vol:vol). Phospho-
rus content was determined with a modified Bartlett procedure
[20]. Phospholipid species were separated by thin-layer chro-
matography. An aliquot containing 300 nmol phosphorus was
evaporated, and the residue dissolved in 100 pi chloroform:
methanol (2:1, vol:vol) and spotted onto the plate. Separation of
phospholipid species was achieved using a solvent composed of
chloroform: methanol: acetic acid:water (100:50:16:4, vol:vol).
Phospholipids were visualized with iodine, scraped from the
plate, and phosphorus content of the various species (lysophos-
phatidylcholine, LPC, sphingomyelin, phosphatidylcholine,
PC, and phosphatidylethanolamine) in each lipoprotein was
determined with the modified Bartlett procedure [20].
Calculations and statistical analysis
The data derived from all rats (NS, NAR and controls) fed the
semisynthetic diet were compared. Data from the NS rats
injected with the low and high doses of adriamycin were
averaged as the degree of proteinuria at the time of sacrifice was
similar (vide infra). A separate analysis was performed on the
data derived from the animals fed the standard rat chow, with or
without cholesterol supplementation. Phosphorus concentra-
tions of each phospholipid were summed for all lipoproteins and
LDP, and the percentage of total phosphorus content of this
phospholipid in each particular fraction was calculated. The
LCAT activity and molar esterification rate were expressed as
a percentage of the mean value found in the matched controls
that were analyzed in the same run. Comparisons were per-
formed using analysis of variance and a t-test with Bonferroni
correction for multiple comparisons where necessary. All re-
sults are expressed as mean SEM.
Results
Lecithin:cholesterol acyltransferase (LCAT) activity
measured with endogenous or excess
exogenous substrates
Nephrotic syndrome. Urinary protein excretion in NS rats
injected with the low dose of adriamycin was 563 76 mg/day
as compared to 76 16 mg/day in the controls (P < 0.001).
Creatinine clearance was reduced by about 20% in the NS rats.
LCAT activity levels using excess exogenous substrate were
increased by about 70% in the NS rats versus controls (P <
0.01), but plasma esterification rates were not different between
these two groups (Table 1). The high levels of unesterified
cholesterol in the NS rats (2.08 0.25 mmol/liter vs. 0.77
0.04 mmollliter in the controls; P < 0.01) gave rise to reduced
fractional esterification rates, despite the absence of differences
in the absolute rate.
Analbuminemia. In the NAR rats both LCAT activity mea-
sured with excess exogenous or with endogenous substrates
(plasma esterification rate) were significantly increased versus
controls (P < 0.01) and versus the values found in the NS rats
(P < 0.01; Table 1). The high levels of unesterified cholesterol
in the NAR (6.62 0.21 mmol/litervs. 1.83 0.04 mmollliterin
Table 1. LCAT activity (exogenous substrate) and endogenous
cholesterol esterification rates (CER) in rats with chronic adnamycin
nephrosis (NS), analbuminemic rats (NAR) and control rats (CON)
N LCAT (% of CON) CER (% of CON)
CON 6 100±3 100±6
NS 6 174±16a 91±11
CON 6 100±4 100±6
NAR 6 232 13ab 174
Samples from the experimental animals were analyzed together with
those obtained from controls matched for age and diet. Data are mean
SEM.
a P < 0.01 vs. CON
b P < 0.01 vs. NS
Table 2. Albumin, cholesterol and phospholipid concentration
(mmol/liter) and phospholipid composition in plasma (% of total) in
rats with chronic adriamycin nephrosis (NS), analbuminemic rats
(NAR) and control rats (CON)
CON NS NAR
N 11 12 12
Albumin glliter
Cholesterol mmollliter
45.7 1.3
2.5 0.2
19.0 3.1"
10.5 1.6"
<01bd
5.5 04ad
Phospholipid mmo/Iliter 1.9 0.1 5.7 07b 3.5 0.2c
N (pooled samples)
Lysophosphatidylcholine %
4
35.2 2.3
4
27.5 1.Oa
4
17.1 0.4"
Sphingomyelin %
Phosphatidylcholine %
9.3 1.9
54.9 0.8
16.2 2.2
53.1 3.1
8.9 0.6c
70.6 0.9"
Phosphoethanolamine % 0.8 0.1 3.2 0.4 3.5 0.3
Data are mean SEM.
a P < 0.05 vs. CON
b P < 0.01 vs. CON
P < 0.05 vs. NS
d P < 0.01 vs. NS
the controls; P < 0.01) gave rise to reduced fractional esterifi-
cation rates, despite the increase in the absolute rate. The
difference in unesterified cholesterol (see above) between the
two groups of control rats is due to differences in age and diet.
Phospholipid composition of lipoproteins and lipoprotein-
deficient plasma
Nephrotic syndrome. Urinary protein excretion in NS rats
injected with the high dose of adriamycin was 765 47 mg/day
as compared to 44 5 mg/day in the controls (P < 0.001).
Creatinine clearance was reduced by about 50% in these NS
rats. Plasma albumin levels were considerably reduced in all the
NS rats (Table 2). Total plasma cholesterol and phospholipid
concentrations in NS rats as compared to controls were in-
creased (P < 0.01; Table 2). Cholesterol levels were higher than
controls in all lipoproteins (P < 0.05 except for IDL; Fig. 1).
Phospholipid levels showed a pattern similar to that of choles-
terol, being higher than controls in all lipoproteins (P < 0.05),
except in HDL3 and the LDP fraction (Fig. 2). The relative
amount of LPC in whole plasma was slightly lower in NS than
in controls (P < 0.05). The relative amounts of PC, sphingomy-
elm and phosphoethanolamine were not significantly altered in
nephrotic as compared to control plasma (Table 2).
PC, the major phospholipid species (Table 2), peaked in
LDL2 and HDL2 in both NS and control rats (Fig. 3). A similar
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Fig. 1. Total cholesterol levels (mmol/liter) in lipoproteins and lipid
deficient plasma of control (CON, , n = 12), nephrotic (NS, N
12) and analbuminemic (NAR, U, N = 5) rats. Data are mean SEM.
Abbreviations are: VLDL, very low density lipoprotein; IDL, interme-
diate density lipoprotein; LDL, low density lipoprotein; HDL, high
density lipoprotein; LDP, lipoprotein-deficient plasma. *D < 0.05 vs.
CON; **<0.01 vs. CON; #P <0.05 vs. NAR; ##P <0.01 vs. NAR.
Fig. 2. Total phospholipid levels (mmol/liter) in lipoproteins and lipid
deficient plasma of control (, N = 12), nephrotic (, N = 12) and
analbuminemic (U, N = 5) rats. Data are mean SEM. Abbreviations
and symbols are in Fig. 1.
pattern was observed for the minor phospholipids, sphingomy-
elm and phosphatidylethanolamine (not shown). The only sig-
nificant difference between NS and control rats was an increase
in the LDL1 fraction in the NS rats (P < 0.05). LPC peaked in
HDL3 and the LDP fraction in control rats. In these fractions
LPC levels were strongly decreased in the NS rats (both P <
0.01). However, in the LDL1, LDL2 and HDL2 fractions LPC
showed a marked increase in the NS rats (all P < 0.05; Fig. 4).
Consequently, LPC was five times as high in LDL1 and LDL2
in the NS rats as compared to LDL1 and LDL2 in the control
rats. Note that part of the LPC content of the HDL3 fraction in
the CON rats is probably due to contamination by albumin from
the adjacent LDP fraction [14].
Analbuminemia. Albumin could not be detected in plasma of
NAR rats. Total cholesterol and phospholipid concentrations
were increased as compared to controls, but lower than in NS
(both P < 0.05; Table 2). Lipoprotein cholesterol levels were
intermediate between NS and control rats, the highest level
being found in the HDL2 fraction (P <0.05 vs. control; Fig. 1).
Phospholipid levels were increased slightly in the VLDL and
VLDL DL LDL1 LDL2 HDL2 HDL3 LDP
Fig. 3. Phosphatidylcholine (PC) levels (% of total PC) in lipoproteins
and lipid deficient plasma of control (u), nephrotic () and analbu-
minemic (U) rats. Data are mean SEM of 4 pooled samples in each
group. Abbreviations and symbols are in Fig. 1.
Fig. 4. Lysophophatidylcholine (LPC) levels (% of total LPC) in Ii-
poproteins and lipid deficient plasma of control (D), nephrotic () and
analbuminemic (U) rats. Data are mean SEM of 4 pooled samples in
each group. Abbreviations and symbols are in Fig. 1.
both LDL fractions, and significantly (P < 0.05 vs. control) in
the HDL2 fraction. However, in the LDP fraction there was a
marked reduction of phospholipid content in the NAR (P < 0.01
vs. both control and NS; Fig. 2). The relative amounts of LPC
in whole plasma were decreased in NAR as compared to both
control and NS rats (P < 0.01), whereas that of PC was
increased as compared to control and NS rats (P < 0.01; Table
2). The relative amount of phosphoethanolamine was higher in
NAR as compared to control plasma (P < 0.05; Table 2).
PC peaked in LDL2 and HDL2 in NAR rats as was also
observed in NS and control rats (Fig. 3). In NAR LPC was
significantly increased in both LDL and the HDL2 fraction (all
P < 0.05) and markedly decreased in the HDL3 and LDP
fractions (both P < 0.01; Fig. 4). Consequently, LPC was four
to five times as high in LDL in the NAR as compared to LDL
in the control rats. There were no significant differences be-
tween NAR and NS rats in the relative distribution of either PC
or LPC.
Dietary cholesterol. Dietary supplementation with choles-
terol with or without cholic acid did not affect plasma albumin
levels (Table 3). Dietary supplementation with 2% cholesterol
had no effect on total plasma cholesterol and phospholipid
levels, whereas the addition of 0.5% cholic acid caused a
*
**
#
**
L
0
E
E
0
a)
(I)
a)0
()
0I-
60
'50
a)
ig
40
- 0.
.. 30
a 20Oo
. 0
10
0
**
*
VLDL JDL LDL1 LDL2 HDL2 HDL3 LDP
**
3
60
50
**0
EE 2
0.
0
0.
(I)0
0.
0I-
#
**
#**
*
ci)C
c0
0.
(I)>
-J
*
*
*
*
VLDL IDL LDL1 LDL2 HDL2 HDL3 LDP
**
**
VLDL IDL LDL1 LDL2 HDL2 HDL3 LDP
Joles et al: Lipoprotein phospholipids in nephrotic rats 101
Table 3. Albumin, cholesterol and phospholipid concentration
(mmollliter) and phospholipid composition in plasma (% of total) in
rats fed standard rat chow (control), or rat chow supplemented with
2% cholesterol, or rat chow supplemented with 2% cholesterol and
0.5% cholic acid
Diet
Control 2% Chol.
2% Chol. +
0.5% chol. ac.
N 10 4 4
Albumin glliter 39.3 0.6 38.8 0.2 39.2 0.6
Cholesterol mmol/liter 2.35 0.10 2.87 0.24 8.81 l.l3c
Phospholipid mmol/liter 1.63 0.09 1.47 0.06 2.40 018bc
N (pooled samples) 3 2 2
Lysophosphatidyicholine % 34.7 1.7 25.9 2.8 27.4 4.1
Sphingomyelin % 10.4 0.7 6.3 0.5 6.9 1.8
Phosphatidylcholine % 53.5 2.0 63.1 2.0 63.7 3.1
Phosphoethanolamine % 1.5 0.4 4.7 1.4 2.1 0.8
Data are mean SEM.
a P < 0.05 vs. controlb P < 0.01 vs. control
P < 0.01 vs. cholesterol only
J # **
VLDL IDL LDL1 LDL2 HDL2 HDL3 LDP
Fig. 5. Total cholesterol levels (mmol/liter) in lipoproteins and lipid
deficient plasma of rats fed standard rat chow (, N = 6), rats ftd rat
chow supplemented with 2% dietary cholesterol (, N = 4), and rats
fed rat chow supplemented with 2% dietary cholesterol plus 0.5% cholic
acid (•, N = 4). Data are mean SEM. Abbreviations are in Fig. 1.
*p < 0.05 vs. CON; ** < 0.01 vs. CON; #P < 0.05 vs. 2% dietary
cholesterol; ##P < 0.01 vs. 2% dietary cholesterol.
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Fig. 6. Total phospholipid levels (mmol/liter) in lipoproteins and lipid
deficient plasma of rats fed standard rat chow (, N = 6), rats fed rat
chow supplemented with 2% dietary cholesterol (, N = 4), and rats
fed rat chow supplemented with 2% dietary cholesterol plus 0.5% cholic
acid (U, N = 4). Data are mean SEM. Symbols are in Fig. 5.
Fig. 7. Phosphatidylcholine (PC) levels (% of total PC) in lipoproteins
and lipid deficient plasma of rats fed standard rat chow (, N =3 X 3),
rats fed rat chow supplemented with 2% dietary cholesterol (, N = 2
x 2), and rats fed rat chow supplemented with 2% dietary cholesterol
plus 0.5% cholic acid (•, N = 2 x 2). Data are mean SEM. Symbols
are in Fig. 5.
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marked hyperlipidemia (P < 0.01 vs. both other groups; Table
3). Cholesterol and phospholipid distribution were affected by
dietary cholesterol supplementation alone. VLDL cholesterol
and phospholipid concentrations were increased (P < 0.05 vs.
control) whereas in the LDL2 particles cholesterol and phos-
pholipid levels were reduced (P < 0.05; Figs. 5 and 6). Dietary
supplementation with cholesterol as well as cholic acid, accen-
tuated the changes observed with cholesterol supplementation
only. VLDL and IDL cholesterol and phospholipid levels were
markedly increased (all P < 0.01), whereas LDL2 and HDL2
cholesterol and phospholipid levels were decreased (P < 0.05;
Figs. 5 and 6). The relative distribution of total phospholipid in
the four phospholipid species was not significantly affected by
dietary cholesterol supplementation with or without cholic acid,
with the exception of a small decrease in sphingomyelin (Table
3).
PC was significantly increased in the VLDL fraction (P <
0.05), and decreased in both LDL fractions (P < 0.01) in the
rats fed with dietary cholesterol only. PC was markedly in-
creased in the VLDL (P < 0.01) and IDL fractions (P <0.05),
and decreased in both LDL and the HDL2 fraction (all P <
0.01) in the rats fed cholesterol with cholic acid (Fig. 7). There
was some increase in LPC content of VLDL and IDL in the
groups with dietary cholesterol, particularly in the groups with
cholic acid supplementation (P < 0.05). However, more than
70% of LPC was localized in HDL3 and the LDP fraction in the
control and cholesterol-fed groups, and more than 50% in the
cholesterol + cholic acid group (Fig. 8).
Thus in all groups studied the distribution of PC, quantita-
tively the major phospholipid, correlated with that of plasma
cholesterol (cf. Figs. I and 3 as well as 5 and 7), whereas LPC
was primarily bound to HDL3 and the LDP fraction in normoal-
buminemic animals, with or without hyperlipidemia, and pri-
marily bound to lipoproteins, in particular LDL1, LDL2 and
HDL2, in hypoalbuminemic animals (cf. Figs. 4 and 8).
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VLDL IDL LDL1 LDL2 HI
—
Fig. 8. Lysophosphatidyicholine (LPC) levels (% of total LPC) in
lipoproteins and lipid deficient plasma of rats fed standard rat chow (,
N = 3 x 3), rats fed rat chow supplemented with 2% dietary cholesterol(, N = 2 x 2), and rats fed rat chow supplemented with 2% dietary
cholesterol plus 0.5% cholic acid (U N = 2 x 2). Data are mean SEM.
Symbols are in Fig. 5.
Discussion
Abnormal lipoprotein composition may contribute to the high
incidence of atherosclerosis in patients with the nephrotic
syndrome [21] and to the further deterioration of their renal
function [22]. The low HDL2 levels observed in some nephrotic
patients [5, 6, 23] may be linked to several defects in the
so-called reverse cholesterol transport. One of these putative
defects is a low cholesterol esterification rate [7, 8]. Lecithin:
cholesterol acyl transferase (LCAT) is a key enzyme for the
esterification of cholesterol in plasma [1].
In the present study, we demonstrate that LCAT activity
measured by esterification of endogenous lipoprotein choles-
terol was not decreased in nephrotic rats, and that in fact LCAT
activity measured with excess exogenous substrate was in-
creased. The latter has also been observed in patients with the
nephrotic syndrome [9]. Reduced fractional esterification rates
(that is, the % of plasma free cholesterol esterified per hour)
have been reported in nephrotic patients [7] and rats [10], but
this is because total unesterified ("free") cholesterol levels are
increased due to the increase in total lipoprotein mass. Our
results in adriamycin-induced nephrosis indicate a normal mo-
lar (as opposed to fractional) esterification rate.
It is not clear why the increased LCAT activity in nephrotic
plasma did not result in an increase in molar esterification rate.
It has been suggested that low LCAT activity in the nephrotic
syndrome may be linked to depletion of albumin [7], the
acceptor of the reaction product, LPC [131. However, our
finding of an increased esterification rate in the NAR argues
against this possibility. Apparently albumin is not the obligatory
acceptor of LPC (vide infra). It is possible that HDL derived
from NS rats is not as good a substrate as HDL from NAR, and
that this difference is somehow related to the presence of
proteinuria in the NS rats. Whether this also holds for nephrotic
patients is unknown. An explanation for the reduced HDL2
levels observed in some nephrotic patients may be the reported
increased plasma cholesterol ester transfer protein (CETP)
activity [9, 24, 25]. CETP activity is virtually absent in rats [26].
LPC has been reported to constitute about 20 to 30% of total
phospholipid in rat plasma [10, 13, 27]. In the present study a
similar value was found in most groups. Note that these values
are considerably higher than the value of about 9% observed in
human plasma [13, 28, 29]. In plasma from control animals more
than 80% of LPC was bound to the albumin-containing fractions
(LDP and HDL3) as has been shown previously in normal
human plasma [29]. More than 50% of LPC was found in LDP
and HDL3 from normoalbuminemic rats with dietary-induced
hyperlipidemia. In contrast, in both NAR and hypoalbumine-
mic NS rats, 80% of the LPC was bound to lipoproteins rather
than to lipoprotein-deficient plasma (LDP) and HDL3. Thus
albumin is apparently not the obligatory acceptor of LPC, and
the alteration in LPC distribution in the hypoalbuminemic state
is not simply the consequence of hyperlipidemia. Indeed, the
alteration in LPC distribution was similar in NAR and NS rats
despite the fact that the degree of hyperlipidemia was much
more severe in the NS rats. Plasma albumin levels were
somewhat reduced in the NS rats; however, the decrease was
not as dramatic as in the NAR. Thus there does not seem to be
a direct inverse correlation between low albumin levels and the
alteration in LPC distribution.
It is not clear how much of the increased LPC k.vel in
lipoproteins in hypoalbuminemic plasma is due to an increase in
cholesterol esterification due to LCAT activity. Enzymatic
modification of lipoproteins by enzymes other than LCAT
should be considered. For instance, increased phospholipase
A2 activity may play a role in the conversion of PC to LPC [301.
Both high phospholipase A2 and high LPC levels are character-
istic of oxidative modification of LDL [30]. However, it should
be noted that LPC levels were increased in all lipoproteins,
including HDL which does not contain apo B, whereas phos-
pholipase A2 activity appears to be a property of apo B itself
[301. Decreased albumin levels may result in a non-specific shift
of LPC to those lipoproteins that are most abundant.
High LPC levels in LDL in hypoalbuminemic states such as
the nephrotic syndrome where LPC appears to be predomi-
nantly bound to lipoproteins may not be innocuous. LDL
oxidized in vitro (by incubation with cultured endothelial cells)
contains much more LPC than native LDL (16 times as much)
[31]. LPC in oxidized LDL is a chemotactic factor for mono-
cytes and probably mediates their entry into the developing
atherosclerotic lesion [32]. Decreased arterial relaxation is a
characteristic of atherosclerotic arteries [33]. Transfer of LPC
from oxidized LDL to endothelial membranes can cause
marked impairment of endothelium-dependent arterial relax-
ation [34, 35]. Pertinent to our findings is the observation that
adding albumin to oxidized LDL largely restored endothelium-
dependent arterial relaxation [34]. Thus, although high LPC
levels in LDL and other lipoproteins do not necessarily imply
that these particles have been oxidatively modified, the altered
phospholipid composition on the surface of these particles may
have a biological effect. It is conceivable that lipoprotein-bound
LPC plays a role in the high incidence of ischemic heart disease
observed in nephrotic patients [36—38].
In summary, this study presents data indicating that plasma
cholesterol esterification is not impaired in rats with nephrotic
syndrome as compared to control rats, while LCAT activity
measured with excess exogenous substrate is increased. In the
presence of hypoalbuminemia, lipoproteins, including LDL,
carry more than 80% of LPC as compared to less than 20% in
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controls. In the presence of normoalbuminemia, hypercholes-
terolemia does not induce this alteration in LPC distribution.
The altered phosphofipid composition of lipoproteins in the
hypoalbuminemic state, that is also characteristic of lipopro-
teins that have been oxidatively modified in vitro, has not been
reported previously in vivo. If similar abnormalities occur in
humans with hypoalbuminemia, they may well contribute to the
high incidence of atherosclerosis observed in patients with the
nephrotic syndrome.
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